Voyageur Book Value Per Share vs Free Cash Flow Yield Analysis
VM Stock | CAD 0.07 0.01 8.33% |
Voyageur Pharmaceuticals financial indicator trend analysis is much more than just breaking down Voyageur Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Voyageur Pharmaceuticals is a good investment. Please check the relationship between Voyageur Pharmaceuticals Book Value Per Share and its Free Cash Flow Yield accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Voyageur Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Book Value Per Share vs Free Cash Flow Yield
Book Value Per Share vs Free Cash Flow Yield Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Voyageur Pharmaceuticals Book Value Per Share account and Free Cash Flow Yield. At this time, the significance of the direction appears to have pay attention.
The correlation between Voyageur Pharmaceuticals' Book Value Per Share and Free Cash Flow Yield is -0.85. Overlapping area represents the amount of variation of Book Value Per Share that can explain the historical movement of Free Cash Flow Yield in the same time period over historical financial statements of Voyageur Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Voyageur Pharmaceuticals' Book Value Per Share and Free Cash Flow Yield is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Book Value Per Share of Voyageur Pharmaceuticals are associated (or correlated) with its Free Cash Flow Yield. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Yield has no effect on the direction of Book Value Per Share i.e., Voyageur Pharmaceuticals' Book Value Per Share and Free Cash Flow Yield go up and down completely randomly.
Correlation Coefficient | -0.85 |
Relationship Direction | Negative |
Relationship Strength | Significant |
Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Free Cash Flow Yield
A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.Most indicators from Voyageur Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Voyageur Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Voyageur Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Voyageur Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Enterprise Value Over EBITDA is likely to climb to 11.97 in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 1.2 M in 2024.
Voyageur Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Voyageur Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Voyageur Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.3M | 2.6M | 2.1M | 2.2M | 2.5M | 2.6M | |
Total Current Liabilities | 910.3K | 621.1K | 591.3K | 673.9K | 775.0K | 418.5K | |
Total Stockholder Equity | 306.3K | 1.9M | 1.5M | 1.4M | 1.7M | 1.7M | |
Net Debt | 265.4K | (770.9K) | (6.0K) | 37.9K | 43.6K | 45.8K | |
Cash | 3.0K | 813.0K | 31.6K | 2.1K | 1.9K | 1.8K | |
Cash And Short Term Investments | 3.0K | 813.0K | 31.6K | 2.1K | 1.9K | 1.8K | |
Net Receivables | 12.7K | 41.5K | 23.9K | 35.9K | 41.3K | 35.5K | |
Common Stock Shares Outstanding | 70.5M | 94.7M | 107.8M | 130.5M | 150.1M | 157.6M | |
Liabilities And Stockholders Equity | 1.3M | 2.6M | 2.1M | 2.2M | 2.5M | 2.6M | |
Total Liab | 968.8K | 660.6K | 630.8K | 727.9K | 837.1K | 484.9K | |
Total Current Assets | 25.5K | 887.3K | 157.2K | 88.6K | 101.9K | 96.8K | |
Retained Earnings | (3.9M) | (6.0M) | (7.7M) | (9.1M) | (8.2M) | (7.8M) | |
Other Stockholder Equity | 791.1K | 1.6M | 1.6M | 1.9M | 2.1M | 2.2M | |
Other Current Liab | 49.1K | 24.0K | 1.0 | 673.7K | 774.7K | 813.4K | |
Net Tangible Assets | 515.7K | 754.1K | 306.3K | 1.9M | 2.2M | 2.3M | |
Property Plant And Equipment Net | 1.2M | 1.7M | 1.9M | 5.8K | 6.7K | 6.4K | |
Accounts Payable | 662.4K | 584.7K | 591.3K | 218.01 | 250.71 | 238.18 | |
Non Current Assets Total | 1.2M | 1.7M | 1.9M | 2.1M | 2.4M | 1.3M | |
Other Current Assets | 12.67 | 23.1K | 91.4K | 76.2K | 87.7K | 61.2K | |
Common Stock | 3.4M | 6.3M | 7.6M | 8.7M | 10.0M | 10.5M | |
Property Plant Equipment | 1.0M | 1.2M | 1.2M | 1.7M | 1.9M | 974.4K | |
Non Current Liabilities Total | 38.1K | 58.5K | 39.5K | 54K | 48.6K | 46.2K | |
Short Long Term Debt Total | 268.4K | 42.1K | 25.5K | 40K | 36K | 34.2K | |
Net Invested Capital | 545.3K | 1.9M | 1.5M | 1.5M | 1.7M | 1.1M | |
Net Working Capital | (884.8K) | 266.2K | (434.1K) | (585.2K) | (673.0K) | (706.7K) | |
Short Term Debt | 8.6K | 114.5K | 223.9K | 16.6K | 19.0K | 18.1K | |
Capital Stock | 3.4M | 6.3M | 7.6M | 8.7M | 10.0M | 5.7M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Voyageur Stock Analysis
When running Voyageur Pharmaceuticals' price analysis, check to measure Voyageur Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Voyageur Pharmaceuticals is operating at the current time. Most of Voyageur Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Voyageur Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Voyageur Pharmaceuticals' price. Additionally, you may evaluate how the addition of Voyageur Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.